Nektar Therapeutics

Day range

$36.94 – $37.92

Open

$37.18

Prev close

$37.22

Volume

171.69K

Market cap

$1.27B

Shares out

34.14M

P/E

—

P/S

23.28

P/B

1.41

P/FCF

—

ROE

-17.4%

ROA

-14.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationOct 1, 2026

  On October 1, 2026, the Company made available a presentation that includes certain additional information regarding its Phase 2b REZOLVE-AA (alopecia areata) clinical trial.

• Material litigationSep 25, 2026

  On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The jury awarded the Company $90 million in damages plus interest to be determined by the District Court.

• Cfo appointmentMay 8, 2026

  Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company. Ms. Rubinstein has over 35 years of operational, financial and capital markets experience in life sciences and investment banking and has been Chief Financial Officer of numerous public and private companies.

• Public offeringApr 23, 2026

  On April 21, 2026, Nektar Therapeutics entered into an underwriting agreement relating to an underwritten offering of 3,532,609 shares of the Company's common stock at a price to the public of $92.00 per Firm Share. The Company also granted the Underwriters a 30-day option to purchase up to an additional 529,891 shares of Common Stock, which the Underwriters exercised in full on April 22, 2026.

• Business updateApr 20, 2026

  On April 20, 2026, Nektar Therapeutics (the "Company") announced it had approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This announcement reflects the Company's estimates based solely upon information available to it as of the date of the announcement.

Days to cover

3.8

Short interest

6.97M

Avg volume

1.85M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
  neutralZacks Investment Research· Oct 15, 2026
• What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
  positiveThe Motley Fool· May 23, 2026
• Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
  negativeGlobeNewswire Inc.· May 5, 2026
• NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & Korsinsky
  negativeGlobeNewswire Inc.· May 4, 2026
• NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th
  negativeGlobeNewswire Inc.· May 4, 2026